Compare · BBI vs MBRX
BBI vs MBRX
Side-by-side comparison of Brickell Biotech Inc. (BBI) and Moleculin Biotech Inc. (MBRX): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. BBI focuses on Biotechnology: Biological Products (No Diagnostic Substances), while MBRX focuses on Biotechnology: Pharmaceutical Preparations.
- BBI is the larger of the two at $23.8M, about 2.0x MBRX ($12.1M).
- MBRX has hit the wire 7 times in the past 4 weeks while BBI has been quiet.
- MBRX has more recent analyst coverage (3 ratings vs 2 for BBI).
- Company
- Brickell Biotech Inc.
- Moleculin Biotech Inc.
- Price
- $2.31+2.90%
- $2.29+0.44%
- Market cap
- $23.8M
- $12.1M
- 1M return
- -
- -12.76%
- 1Y return
- -
- -85.35%
- Industry
- Biotechnology: Biological Products (No Diagnostic Substances)
- Biotechnology: Pharmaceutical Preparations
- Exchange
- NASDAQ
- NASDAQ
- IPO
- 2016
- News (4w)
- 0
- 7
- Recent ratings
- 2
- 3
Brickell Biotech Inc.
Brickell Biotech, Inc., a clinical-stage pharmaceutical company, focuses on identifying, developing, and commercializing various prescription therapeutics for the treatment of debilitating skin diseases in the United States. The company's lead product candidate is sofpironium bromide that is in phase 3 clinical trial to treat patients with primary axillary hyperhidrosis. It has a collaboration agreement with AnGes, Inc. for the development of a novel DNA vaccine candidate for COVID-19. The company was founded in 2009 and is headquartered in Boulder, Colorado.
Moleculin Biotech Inc.
Moleculin Biotech, Inc., a clinical-stage pharmaceutical company, focuses on the development of oncology drug candidates for the treatment of highly resistant tumors and viruses in the United States. Its lead drug candidate is Annamycin that is in Phase 1/2 studies for the treatment of relapsed or refractory acute myeloid leukemia (AML) and cancers metastasized to the lungs. The company's flagship immune/transcription modulator is WP1066, which is in Phase I clinical trial for the treatment of brain tumors and pediatric brain tumors, as well as pancreatic cancer and hematologic malignancies. It also develops WP1220, an analog of WP1066, which has completed Phase 1 clinical trial for the topical treatment of cutaneous T-cell lymphoma in Poland; WP1234 for the treatment of pancreatic cancer; and WP1732, an analog of WP1066 for the treatment of topical treatment of cutaneous T-cell lymphoma. The company's lead metabolism/glycosylation inhibitor compound is WP1122 to treat cancers and viruses. In addition, it engages in the preclinical development of other drug candidates, including other immune/transcription modulators and antimetabolites, targeting glycolysis and glycosylation. The company has partnerships and collaboration agreement with MD Anderson, DERMIN Sp. z o. o., Animal Life Sciences, LLC, and WPD Pharmaceuticals Sp z.o.o for the development of various drug candidates. Moleculin Biotech, Inc. was incorporated in 2015 and is headquartered in Houston, Texas.
Latest BBI
- Spruce Point Capital Management Announces Investment Opinion: Releases Report and Strong Sell Research Opinion on Floor & Decor Holdings, Inc. (NYSE: FND)
- SEC Form 10-Q filed by Brickell Biotech Inc.
- Brickell Biotech Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
- Brickell Biotech Inc. filed SEC Form 8-K: Leadership Update, Financial Statements and Exhibits
- Fresh Tracks Therapeutics Initiates Multiple Ascending Dose Portion of Phase 1 Study of DYRK1A Inhibitor FRTX-02
- SEC Form EFFECT filed by Brickell Biotech Inc.
- Brickell Biotech Inc. filed SEC Form 8-K: Amendments to Articles of Incorporation or Bylaws; Change in Fiscal Year, Financial Statements and Exhibits
- Brickell Biotech's Return On Capital Employed Insights
- Brickell Biotech Announces Corporate Rebranding to Fresh Tracks Therapeutics
- SEC Form DEL AM filed by Brickell Biotech Inc.
Latest MBRX
- Moleculin CEO, Walter Klemp, Highlights Positive Preliminary MIRACLE Trial Results in Virtual Investor "What This Means" Segment
- Moleculin Biotech Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Moleculin Biotech Inc. filed SEC Form 8-K: Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Moleculin Reports Positive Phase 2/3 MIRACLE Interim Results, With Annamycin Complete Remission Rates 3-fold Greater than Control
- Chief Science Officer Picker Donald H converted options into 115 shares and covered exercise/tax liability with 34 shares, increasing direct ownership by 12% to 753 units (SEC Form 4)
- CEO and President Klemp Walter V covered exercise/tax liability with 125 shares and converted options into 510 shares, increasing direct ownership by 1% to 31,007 units (SEC Form 4)
- Chief Financial Officer Foster Jonathan P. converted options into 283 shares and covered exercise/tax liability with 72 shares, increasing direct ownership by 2% to 12,340 units (SEC Form 4)
- Moleculin Biotech Inc. filed SEC Form 8-K: Regulation FD Disclosure, Financial Statements and Exhibits
- Independent Market Research Finds Strong Physician Intent to Prescribe Moleculin's Annamycin in Relapsed/Refractory AML
- Moleculin CEO, Walter Klemp, Highlights 45 Subject Enrollment Milestone in Recent Virtual Investor "What This Means" Segment